SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ — DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics’ next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, “We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs, we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform.”
ข่าวที่เกี่ยวข้อง
- Connect Every Customer, Every Machine, Every Jobsite: XCMG CONNECT Reshapes Industrial Service Ecosystem
- State Grid Dingxi Anding District Power Supply Company: On-site Inspection for Electrical Hazards to Ensure Stable Power Supply for Anding District Science and Technology Museum
- Luckin Coffee Surpasses RMB20 Billion in Non-Coffee Beverage Sales, Expands Global Store Network Beyond 35,000
- Shinsung Materials Strengthens Global Presence with High-Performance Personal Care Ingredients
